XML 13 R48.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Commitments and Contingencies (Details Textual 1) (USD $) | 1 Months Ended | 0 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 1 Months Ended | 9 Months Ended | 12 Months Ended |  | 9 Months Ended | 12 Months Ended | 0 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended | 9 Months Ended |  |  | 1 Months Ended |  | 1 Months Ended | 9 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 31, 2012 | Aug. 01, 2012 Rental Agreement [Member] | Sep. 30, 2013 Rental Agreement [Member] | Sep. 30, 2013 Abbott Biotherapeutics Corp [Member] Product Development and Patent License Agreement [Member] | Dec. 31, 2012 Abbott Biotherapeutics Corp [Member] Product Development and Patent License Agreement [Member] | Sep. 30, 2013 Abbott Biotherapeutics Corp [Member] After First Net Sales [Member] | Dec. 31, 2012 Abbott Biotherapeutics Corp [Member] After First Net Sales [Member] | Sep. 30, 2013 Abbott Biotherapeutics Corp [Member] After First Net Sales [Member] Product Development and Patent License Agreement [Member] | Dec. 31, 2012 Abbott Biotherapeutics Corp [Member] After First Net Sales [Member] Product Development and Patent License Agreement [Member] | Sep. 30, 2013 Abbott Biotherapeutics Corp [Member] Phase I Clinical Trial of a licensed product [Member] | Dec. 31, 2012 Abbott Biotherapeutics Corp [Member] Phase I Clinical Trial of a licensed product [Member] | Dec. 31, 2012 Abbott Biotherapeutics Corp [Member] Phase I Clinical Trial of a licensed product [Member] Product Development and Patent License Agreement [Member] | Feb. 28, 2002 Memorial Sloan Kettering Cancer Center [Member] License agreement [Member] | Sep. 30, 2013 Memorial Sloan Kettering Cancer Center [Member] License agreement [Member] | Dec. 31, 2012 Memorial Sloan Kettering Cancer Center [Member] License agreement [Member] | Mar. 27, 2012 Memorial Sloan Kettering Cancer Center [Member] Clinical Trial Agreement [Member] | Sep. 30, 2013 Oak Ridge National Laboratory [Member] | Dec. 31, 2012 Oak Ridge National Laboratory [Member] | Aug. 06, 2012 Aptiv Solutions [Member] | Sep. 30, 2013 Aptiv Solutions [Member] | Dec. 31, 2012 Aptiv Solutions [Member] | Dec. 31, 2007 Aptiv Solutions [Member] | Aug. 12, 2013 Fred Hutchinson Cancer Research Center [Member] license and sponsored research agreement [Member] | Jun. 15, 2012 Fred Hutchinson Cancer Research Center [Member] license and sponsored research agreement [Member] | Jun. 15, 2012 Fred Hutchinson Cancer Research Center [Member] license and sponsored research agreement [Member] | Sep. 30, 2013 Fred Hutchinson Cancer Research Center [Member] license and sponsored research agreement [Member] | Jun. 15, 2012 Fred Hutchinson Cancer Research Center [Member] license and sponsored research agreement [Member] Maximum [Member] | Jun. 15, 2012 Fred Hutchinson Cancer Research Center [Member] license and sponsored research agreement [Member] Minimum [Member] | Jul. 19, 2012 Fred Hutchinson Cancer Research Center [Member] Clinical Trial Agreement [Member] | Aug. 28, 2012 University of Texas M.D. Anderson Cancer Center [Member] Clinical Trial Agreement [Member] Note | Sep. 26, 2012 Johns Hopkins University [Member] Clinical Trial Agreement [Member] | Nov. 21, 2012 University of Pennsylvania [Member] Clinical Trial Agreement [Member] | May 09, 2011 Jamess Capital Group LLC [Member] Transaction management agreement [Member] | Mar. 31, 2013 Former CEO [Member] Separation and Settlement Agreement [Member] | Feb. 28, 2013 Former CEO [Member] Separation and Settlement Agreement [Member] Note | Sep. 30, 2013 Former CEO [Member] Separation and Settlement Agreement [Member]
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License fee payment |  |  |  | $ 3,000,000 | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones payments |  |  |  | 7,750,000 | 7,750,000 | 1,500,000 | 1,500,000 |  |  | 750,000 | 750,000 | 750,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales in milestones payment |  |  |  |  |  |  |  | 10,000,000 | 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 | 1,000,000 |  |  |  |  |  |  |  |  |  |  |
Milestone payment date |  | Jan. 31, 2013 |  |  | Jul. 24, 2012 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of royalty payment |  |  |  | We agreed to pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of up to 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire. | Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire. |  |  |  |  |  |  |  |  | We agrees to pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire. | Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire. |  |  |  |  |  |  |  |  |  | Royalty payments of 2% of net sales will be due to FHCRC. | Royalty payments of 2% of net sales will be due to FHCRC. |  |  |  |  |  |  |  |  |  |
Royalty of Net Sales Percentage |  |  |  | 12.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
First commercial sale period |  |  |  | 12 years 6 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Technology access fee |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual maintenance fee |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual research funding |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase of radioactive material used for research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 233,100 | 233,100 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Project estimated cost for clinical trials of drug Ac-225-HuM195 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,200,000 | 1,900,000 | 1,859,333 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Down payment of project estimated cost percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12.50% | 12.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Down payment for project |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 239,000 | 239,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical trial cost for approval of food and drug administration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 23,500,000 | 13,200,000 |  |  |  |  |  |  |  |
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years ) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 | 150,000 |  |  |  |  |  |  |  |  |  |  |
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter ) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 250,000 | 250,000 |  |  |  |  |  |  |  |  |  |  |
Royalty payment for the commercial use of drugs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 37,500 |  |  |  |  |  |  |  |  |  |  |  |  |
Number of Patients |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 24 |  |  |  |  |  |
Amount paid to each patient after Completing clinical trial |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 31,185 |  |  |  |  |  |  |  |  |  |  |  |  | 31,366 | 481,204 | 38,501 | 31,771 |  |  |  |
Start-up fee for clinical trial |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 79,623 |  |  |  |  |  |  |  |  |  |  |  |  | 19,749 | 33,946 | 22,847 | 16,000 |  |  |  |
Start-up due cost paid date |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Jul. 10, 2012 |  |  |  |  |  |  |  |  |  |  |  |  | Sep. 30, 2013 | Sep. 30, 2013 |  |  |  |  |  |
Non - refundable institutional fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 14,500 |  |  |  |  |  |
Annual pharmacy fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,025 |  |  |  |  |
Amendment processing fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 500 |  |  |  |  |
Monthly fee received by management firm |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,500 |  |  |
Percentage of fully diluted capital stock equal to common stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10.00% |  |  |
Warrant exercisable notice period description |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | The warrants contain a provision wherein the holder may waive the 90 day exercise notice requirement by giving 65 days prior notice of such waiver. |  |  |
Description of period of shares availability by exercise of warrant |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | The shares available by exercise of this Warrant are also restricted and may not be sold or otherwise transfered until the earlier of twelve months from the closing date of the Pubco Transaction; or for six months after the planned Registration Statement is declared effective. |  |  |
Maximum amount of out of pocket expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000 |  |  |
Consideration pursuant to agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | The Company paid Mr. Talley $125,000 on March 8, 2013 and a second payment of $125,000 on September 1, 2013. The Company also paid Mr.Talley a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012.
Amount payable in installments under agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 250,000 |
Number Of Installments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |
Performance bonus payable under agreement for service |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60,000 |
Rental agreement renewal description |  |  | The agreement automatically renews on a month-to-month basis and requires a two month notice of termination. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of first installment for services by company |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 125,000 |  |
Outstanding payment of final installment for services by company |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 125,000 |  |
Payment of performance bonus for services by company |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 60,000 |  |
Rent agreement termination date | Jan. 31, 2013 | Jan. 31, 2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Notice period for termination of agreement | 60 days prior to January 1, 2013 |  | The agreement terminated May 31, 2013. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Consideration under agreement + References No definition available. + Details
Name: | fil_AgreementConsideration
Namespace Prefix: | fil_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description regarding renewal of agreement. + References No definition available. + Details
Name: | fil_AgreementRenewalDescription
Namespace Prefix: | fil_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amendment processing fee. + References No definition available. + Details
Name: | fil_AmendmentProcessingFee
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount to be paid for each Patient that has completed the clinical trial. + References No definition available. + Details
Name: | fil_AmountPaidToEachPatient
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount payable in installments under agreement. + References No definition available. + Details
Name: | fil_AmountPayableInInstallmentsUnderAgreement
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Clinical trial cost for approval of food and drug administration. + References No definition available. + Details
Name: | fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | fil_CommitmentsAndContingenciesTextualAbstract
Namespace Prefix: | fil_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of royalty payment to related party. + References No definition available. + Details
Name: | fil_DescriptionOfRoyaltyPaymentToRelatedParty
Namespace Prefix: | fil_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of shares availability by exercise of warrant. + References No definition available. + Details
Name: | fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant
Namespace Prefix: | fil_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Down payment for project. + References No definition available. + Details
Name: | fil_DownPaymentForProject
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of total estimated project cost required for down payment. + References No definition available. + Details
Name: | fil_DownPaymentOfProjectEstimatedCostPercentage
Namespace Prefix: | fil_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition First commercial sale period. + References No definition available. + Details
Name: | fil_FirstCommercialSalePeriod
Namespace Prefix: | fil_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fund to related party under agreement after year two. + References No definition available. + Details
Name: | fil_FundToRelatedPartyUnderAgreementAfterYearTwo
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fund to related party under agreement for first two Year. + References No definition available. + Details
Name: | fil_FundToRelatedPartyUnderAgreementForFirstTwoYear
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Long term purchase commitment milestones payment. + References No definition available. + Details
Name: | fil_LongTermPurchaseCommitmentMilestonesPayment
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum amount of out of pocket expenses. + References No definition available. + Details
Name: | fil_MaximumAmountOfOutOfPocketExpenses
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment date. + References No definition available. + Details
Name: | fil_MilestonePaymentDate
Namespace Prefix: | fil_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non refundable institutional fee. + References No definition available. + Details
Name: | fil_NonRefundableInstitutionalFee
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Notice Period for termination of agreement. + References No definition available. + Details
Name: | fil_NoticePeriodForTerminationOfAgreement
Namespace Prefix: | fil_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of installments. + References No definition available. + Details
Name: | fil_NumberOfInstallments
Namespace Prefix: | fil_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of patients. + References No definition available. + Details
Name: | fil_NumberOfPatients
Namespace Prefix: | fil_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Outstanding payment of final installment for services by company. + References No definition available. + Details
Name: | fil_PaymentOfFinalInstallmentForServicesByCompany
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payment of first installment for services by company. + References No definition available. + Details
Name: | fil_PaymentOfFirstInstallmentForServicesByCompany
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License fee payment. + References No definition available. + Details
Name: | fil_PaymentOfLicenseFee
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payment of Performance bonus for Services by Company + References No definition available. + Details
Name: | fil_PaymentOfPerformanceBonusForServicesByCompany
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of fully diluted capital stock equal to common stock. + References No definition available. + Details
Name: | fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock
Namespace Prefix: | fil_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Performance bonus payable under agreement for service. + References No definition available. + Details
Name: | fil_PerformanceBonusPayableUnderAgreementForService
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Periodic fee received by management firm. + References No definition available. + Details
Name: | fil_PeriodicFeeReceivedByManagementFirm
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Pharmacy fee. + References No definition available. + Details
Name: | fil_PharmacyFee
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Project estimated cost. + References No definition available. + Details
Name: | fil_ProjectEstimatedCost
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Purchase of radioactive material. + References No definition available. + Details
Name: | fil_PurchaseOfRadioactiveMaterial
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research and development arrangement. + References No definition available. + Details
Name: | fil_ResearchAndDevelopmentArrangement
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty of net sales percentage. + References No definition available. + Details
Name: | fil_RoyaltyOfNetSalesPercentage
Namespace Prefix: | fil_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Start-up due cost paid date. + References No definition available. + Details
Name: | fil_StartUpDueCostPaidDate
Namespace Prefix: | fil_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | instant

X
- Definition Start-up fee for clinical trial. + References No definition available. + Details
Name: | fil_StartUpFeeForClinicalTrial
Namespace Prefix: | fil_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Warrant exercisable notice period description. + References No definition available. + Details
Name: | fil_WarrantExercisableNoticePeriodDescription
Namespace Prefix: | fil_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Date which lease or group of leases is set to expire, in CCYY-MM-DD format. + References No definition available. + Details
Name: | us-gaap_LeaseExpirationDate1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Costs incurred and are directly related to generating maintenance revenues. Also includes cost of maintenance on client contracts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_MaintenanceCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Costs incurred in providing technology services. The services may include training, installation, engineering or consulting. Consulting services often include implementation support, software design or development, or the customization or modification of the licensed software. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(d)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 605 -Section 25 -Paragraph 76 -URI http://asc.fasb.org/extlink&oid=22169047&loc=d3e132428-111767 + Details
Name: | us-gaap_TechnologyServicesCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration